Late effects of Hodgkin's disease and its treatment

Cancer Journal

Volumn 15, Issue 2, 2009, Pages 164-168

  Ng, Andrea K ^a,b   Mauch, Peter M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ASB1 L2 ^*  (United States)

Author keywords

Complications; Hodgkin's lymphoma; Late effects; Second malignant neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

AMENORRHEA; AZOOSPERMIA; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIGESTIVE SYSTEM CANCER; DOCUMENTATION; EARLY MENOPAUSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FOLLOW UP; HEART DEATH; HEART INFARCTION; HODGKIN DISEASE; HUMAN; HYPOTHYROIDISM; LEUKEMIA; LUNG CANCER; MEDIASTINUM; NONHODGKIN LYMPHOMA; POLLEN; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION INJURY; REVIEW; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SECOND CANCER; SEMEN ABNORMALITY; SMOKING; SOLID TUMOR; THYROID DISEASE; VASCULAR DISEASE;

ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; HODGKIN DISEASE; HUMANS; INFERTILITY; MASS SCREENING; NEOPLASMS, SECOND PRIMARY; RADIATION INJURIES; SURVIVORS; THYROID DISEASES; TIME FACTORS;

EID: 68049148389     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31819e30d7     Document Type: Review

References (56)

1. Henry-Amar M, Hayat M, Meerwaldt JH, et al. Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. EORTC Lymphoma Cooperative Group. Int J Radiat Oncol Biol Phys. 1990;19:1155-1157.
2. Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol. 1997;8(suppl 1):115-118.
3. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002;20:2101-2108. (Pubitemid 34408801)
4. Arseneau JC, Sponzo RW, Levin DL, et al. Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy. N Engl J Med. 1972;287:1119-1122.
5. Kaldor JM, Day NE, Clarke EA, et al. Leukemia following Hodgkin's disease. N Engl J Med. 1990;322:7-13.
6. van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol. 1994;12:1063-1073.
7. Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol. 2004;22:2835-2841. (Pubitemid 41079901)
8. Schonfeld SJ, Gilbert ES, Dores GM, et al. Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35,511 patients. J Natl Cancer Inst. 2006;98:215-218. (Pubitemid 43205483)
9. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348:2386-2395. (Pubitemid 36682817)
10. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20:630-637. (Pubitemid 34111368)
11. van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18:487-497. (Pubitemid 30078530)
12. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol. 2000;18:498-509.
13. Rueffer U, Josting A, Franklin J, et al. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis. J Clin Oncol. 2001;19:2026-2032. (Pubitemid 32702547)
14. Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2005;23:7555-7564. (Pubitemid 46291819)
15. Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007;25:1489-1497. (Pubitemid 46759253)
16. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003;290:465-475. (Pubitemid 37430500)
17. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst. 2003;95:971-980. (Pubitemid 36896714)
18. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst. 2002;94:182-192. (Pubitemid 34162752)
19. Swerdlow AJ, Schoemaker MJ, Allerton R, et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol. 2001;19:1610-1618. (Pubitemid 32230860)
20. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA. 1993;270:1949-1955. (Pubitemid 23312611)
21. Eriksson F, Gagliardi G, Liedberg A, et al. Long-term cardiac mortality following radiation therapy for Hodgkin's disease: analysis with the relative seriality model. Radiother Oncol. 2000;55:153-162. (Pubitemid 30229990)
22. Lee CK, Aeppli D, Nierengarten ME. The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys. 2000;48:169-179. (Pubitemid 30488228)
23. Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42:743-749.
24. Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol. 2004;22:3139-3148.
25. Heidenreich PA, Hancock SL, Vagelos RH, et al. Diastolic dysfunction after mediastinal irradiation. Am Heart J. 2005;150:977-982.
26. Aviles A, Neri N, Nambo JM, et al. Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma. 2005;46:1023-1028. (Pubitemid 40975022)
27. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290:2831-2837.
28. Boivin JF, Hutchison GB, Lubin JH, et al. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer. 1992;69:1241-1247.
29. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol. 1993;11:1208-1215. (Pubitemid 23199121)
30. Glanzmann C, Kaufmann P, Jenni R, et al. Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiother Oncol. 1998;46:51-62. (Pubitemid 28072859)
31. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109:1878-1886. (Pubitemid 46348183)
32. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21:3431-3439. (Pubitemid 46603515)
33. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99:206-214.
34. Heidenreich PA, Schnittger I, Strauss HW, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol. 2007;25:43-49. (Pubitemid 350003049)
35. Bowers DC, McNeil DE, Liu Y, et al. Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2005;23:6508-6515.
36. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med. 1991;325:599-605.
37. Constine LS, Donaldson SS, McDougall IR, et al. Thyroid dysfunction after radiotherapy in children with Hodgkin's disease. Cancer. 1984;53:878-883. (Pubitemid 14183747)
38. Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000;85:3227-3232. (Pubitemid 30944530)
39. Bhatia S, Ramsay NK, Bantle JP, et al. Thyroid Abnormalities after Therapy for Hodgkin's Disease in Childhood. Oncologist. 1996;1:62-67. (Pubitemid 126669373)
40. Clifton DK, Bremner WJ. The effect of testicular x-irradiation on spermatogenesis in man. A comparison with the mouse. J Androl. 1983;4:387-392.
41. Lushbaugh CC, Casarett GW. The effects of gonadal irradiation in clinical radiation therapy: a review. Cancer. 1976;37:1111-1125.
42. Meistrich ML. Effects of chemotherapy and radiotherapy on spermatogenesis. Eur Urol. 1993;23:136-141.
43. Ogilvy-Stuart AL, Shalet SM. Effect of radiation on the human reproductive system. Environ Health Perspect. 1993;101(suppl 2):109-116.
44. Anselmo AP, Cartoni C, Bellantuono P, et al. Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD/MOPP. Haematologica. 1990;75:155-158. (Pubitemid 20203579)
45. van der Kaaij MA, Heutte N, Le Stang N, et al. Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007;25:2825-2832. (Pubitemid 47134677)
46. Viviani S, Santoro A, Ragni G, et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol. 1985;21:601-605. (Pubitemid 15116991)
47. Sieniawski M, Reineke T, Nogova L, et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood. 2008;111:71-76.
48. Williams RS, Littell RD, Mendenhall NP. Laparoscopic oophoropexy and ovarian function in the treatment of Hodgkin disease. Cancer. 1999;86:2138-2142.
49. Williams RS, Mendenhall N. Laparoscopic oophoropexy for preservation of ovarian function before pelvic node irradiation. Obstet Gynecol. 1992;80:541-543.
50. De Bruin ML, Huisbrink J, Hauptmann M, et al. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood. 2008;111:101-108.
51. Hodgson DC, Pintilie M, Gitterman L, et al. Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol. 2007;25:11-15. (Pubitemid 46474309)
52. Koh ES, Sun A, Tran TH, et al. Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2006;66:223-228. (Pubitemid 44175658)
53. Noordijk EM, Thomas J, Fermé C, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). J Clin Oncol. 2005;23:6505a.
54. Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006;79:270-277. (Pubitemid 44109907)
55. Girinsky T, Ghalibafian M. Radiation treatment in non Hodgkin's lymphomas: present and future directions. Cancer Radiother. 2005;9:422-426. (Pubitemid 41719054)
56. Ghalibafian M, Beaudre A, Girinsky T. Heart and coronary artery protection in patients with mediastinal Hodgkin lymphoma treated with intensity-modulated radiotherapy: dose constraints to virtual volumes or to organs at risk? Radiother Oncol. 2008;87:82-88.